Gilead Sciences Pty Ltd v Idenix Pharmaceuticals LLC

The matter in Gilead Sciences Pty Ltd v Idenix Pharmaceuticals LLC was heard by Justice Gilmour of the Federal Court of Australia. Gilead challenged the validity of a patent held by Idenix, asserting various grounds including lack of novelty, internal fair basis, sufficiency, utility, manner of manufacture, and false suggestion. The central issue was whether Idenix's patent was valid and enforceable or if it should be invalidated on the grounds presented by Gilead.

The court examined whether the claims of Idenix's patent were adequately supported by the priority documents and the specification. It was determined that the priority documents provided a real and reasonably clear disclosure of the claims, thus establishing the patent's entitlement to the priority date. Furthermore, the specification sufficiently disclosed the invention, thereby satisfying the requirement for internal fair basis. However, the court found that some claims were insufficiently described, leading to their invalidation on that ground. Regarding utility, certain claims were deemed invalid because they did not demonstrate practical usefulness. The court also rejected Gilead's claims of invalidation on the grounds of lack of manner of manufacture and false suggestion, finding no merit in these arguments.

The court's reasoning concluded that while some claims of Idenix's patent were invalidated due to insufficiency and inutility, Gilead's other challenges were unsuccessful. The judge directed the parties to confer and submit agreed or competing orders within 14 days to reflect these findings. The court’s decision provided clarity on the validity of specific claims while dismissing the majority of Gilead's objections.